- Home
- BIIB vs SW Comparison
BIIB vs SW Comparison
Compare BIIB & SW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- SW
- Stock Information
- Founded
- BIIB 1978
- SW 1934
- Country
- BIIB United States
- SW Ireland
- Employees
- BIIB N/A
- SW N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- SW
- Sector
- BIIB Health Care
- SW
- Exchange
- BIIB Nasdaq
- SW Nasdaq
- Market Cap
- BIIB 24.2B
- SW 21.6B
- IPO Year
- BIIB 1991
- SW N/A
- Fundamental
- Price
- BIIB $175.74
- SW $33.72
- Analyst Decision
- BIIB Buy
- SW Strong Buy
- Analyst Count
- BIIB 23
- SW 10
- Target Price
- BIIB $176.48
- SW $54.40
- AVG Volume (30 Days)
- BIIB 2.0M
- SW 6.4M
- Earning Date
- BIIB 10-30-2025
- SW 10-29-2025
- Dividend Yield
- BIIB N/A
- SW 5.26%
- EPS Growth
- BIIB N/A
- SW 109.82
- EPS
- BIIB 10.97
- SW 1.42
- Revenue
- BIIB $10,065,900,000.00
- SW $31,138,000,000.00
- Revenue This Year
- BIIB $2.97
- SW $52.91
- Revenue Next Year
- BIIB N/A
- SW $3.09
- P/E Ratio
- BIIB $15.97
- SW $23.78
- Revenue Growth
- BIIB 4.77
- SW 89.50
- 52 Week Low
- BIIB $110.04
- SW $32.73
- 52 Week High
- BIIB $176.02
- SW $56.99
- Technical
- Relative Strength Index (RSI)
- BIIB 76.31
- SW 29.47
- Support Level
- BIIB $165.75
- SW $32.73
- Resistance Level
- BIIB $170.78
- SW $34.51
- Average True Range (ATR)
- BIIB 5.16
- SW 0.94
- MACD
- BIIB 1.34
- SW -0.08
- Stochastic Oscillator
- BIIB 98.74
- SW 22.83
About BIIB Biogen Inc.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
About SW Smurfit WestRock plc Ordinary Shares
Smurfit WestRock manufactures corrugated packaging and consumer packaging, such as folding cartons and paperboard. After the merger of Smurfit Kappa and WestRock in summer 2024, Smurfit WestRock became the largest producer of containerboard in the world, with substantial operations in North America, South America, and Europe.